Mouse study links higher hippocampal 2-AG with early fluoxetine response
2-AG as a potential biomarker for predicting response to short-term fluoxetine treatment in a mouse model of depression.
AI Summary
The study asked whether endocannabinoid levels could help identify early response to fluoxetine. Researchers used male mice exposed to chronic unpredictable mild stress, a model of depression, and gave fluoxetine during the final week of the five-week protocol. They measured brain chemicals in the hippocampus and prefrontal cortex and observed behavioral improvement after treatment.
The improvement was accompanied by increased hippocampal 2-arachidonoylglycerol (2-AG) and reduced GABA and glutamate in the prefrontal cortex. The authors suggest that 2-AG may be a marker of early fluoxetine response. This is an abstract-based summary: the findings come from a mouse study and do not establish that 2-AG predicts antidepressant response in people or that the changes caused the behavioral improvement. The abstract does not report sample size or quantitative effect estimates.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
In septic rats, lenabasum reduced lung injury markers over 24 hours
Endocannabinoid levels differed in RA and tracked disease activity in women
Canine tumours show varied CB1 and CB2 expression; treatment effects remain…
Explore More Research
Stay informed about the latest cannabis science.